Electroacupuncture at ST36 for Reducing Postoperative Inflammation After Cardiac Surgery With Cardiopulmonary Bypass

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorSir Run Run Shaw Hospital

About this trial

Cardiac surgery using cardiopulmonary bypass can trigger a marked systemic inflammatory response and may contribute to postoperative organ dysfunction and delayed recovery. Electroacupuncture at the Zusanli acupoint (ST36) may regulate inflammatory responses, but its clinical effects in patients undergoing cardiac surgery remain uncertain.

This prospective, randomized, parallel-group study will enroll 140 adults undergoing elective cardiac surgery with cardiopulmonary bypass. After surgery and admission to the intensive care unit, participants will be randomly assigned in a 1:1 ratio to receive either bilateral ST36 electroacupuncture or a control procedure involving the same acupoint localization, skin disinfection, needle insertion, and needle retention without electrical stimulation. Both groups will receive standard postoperative care. The intervention will be administered twice for 30 minutes per session.

The primary outcomes are C-reactive protein levels and Sequential Organ Failure Assessment scores on postoperative day 2. Secondary outcomes include the duration of vasoactive drug use, incidence and severity of systemic inflammatory response syndrome, duration of mechanical ventilation, length of intensive care unit and hospital stay, and perioperative inflammatory markers. The study will evaluate whether ST36 electroacupuncture can reduce postoperative inflammation and organ injury and improve recovery after cardiac surgery.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Age ≥18 years.

Scheduled to undergo elective cardiac surgery with cardiopulmonary bypass (CPB) support.

The surgical procedure may include coronary artery bypass grafting (CABG), valve replacement, valve repair, or another cardiac surgical procedure performed with CPB support.

Voluntarily agrees to participate in the study and provides written informed consent. If a participant is unable to read and sign the informed consent form because of incapacity or another reason, the informed consent process will be conducted with the participant's legally authorized representative, who will sign on the participant's behalf. If a participant is unable to read the informed consent form, the informed consent process will be witnessed by an independent witness, who will sign the informed consent form.

Disqualifiers

Membership in a vulnerable population other than older adults or individuals who are illiterate, including patients with psychiatric disorders, cognitive impairment, critical illness, or another vulnerable condition.

Pregnant or breastfeeding.

Local skin or soft-tissue infection, erysipelas, or another condition at the acupuncture site that makes acupuncture treatment unsuitable.

History of organ transplantation.

Trial design

Design model

Parallel

Treatments tested in this trial

  • Electroacupuncture at Bilateral ST36

    Other intervention

    Participants assigned to the experimental group will receive electroacupuncture at bilateral Zusanli (ST36) after cardiac surgery and admission to the intensive care unit. Electrical stimulation will be applied through acupuncture needles placed at bilateral ST36. The intervention will be administered twice, with each session lasting 30 minutes, in addition to standard postoperative treatment and nursing care.

  • Acupuncture Without Electrical Stimulation at Bilateral ST36

    Other intervention

    Participants assigned to the control group will receive the same bilateral ST36 acupoint localization, skin disinfection, needle insertion, and needle retention procedures as the experimental group, but without electrical stimulation. The control procedure will be administered twice, with each session lasting 30 minutes, in addition to standard postoperative treatment and nursing care.

Treatment groups

140 Participants
are divided into 2 treatment groups
Group A: Electroacupuncture GroupExperimental treatment 1 intervention
Group B: Acupuncture Without Electrical Stimulation GroupSham comparator 1 intervention

Trial outcomes

Primary outcomes

1

C-Reactive Protein Level on Postoperative Day 2

Serum C-reactive protein concentration measured in milligrams per liter (mg/L). The primary analysis will compare C-reactive protein levels between the two study groups.

Time frame
Postoperative day 2
2

Sequential Organ Failure Assessment Score on Postoperative Day 2

The Sequential Organ Failure Assessment (SOFA) score assesses dysfunction across six organ systems: respiratory, coagulation, liver, cardiovascular, central nervous system, and renal. Each organ system is scored from 0 to 4, and the six component scores are summed to produce a total score ranging from 0 to 24. Higher scores indicate more severe organ dysfunction and therefore a worse outcome.

Time frame
Postoperative day 2

Secondary outcomes

1

Duration of Vasoactive Drug Use

The outcome is defined as the total cumulative duration, measured in hours, of continuous intravenous norepinephrine and/or epinephrine administration during the postoperative intensive care unit (ICU) stay. Drug administration start and stop times will be obtained from the nursing medication administration records. The observation period begins at postoperative ICU admission and ends at ICU discharge.

Time frame
The outcome is defined as the total cumulative duration, measured in hours, of continuous intravenous norepinephrine and/or epinephrine administration during the postoperative ICU stay, an average of 2 days.
2

Systemic Inflammatory Response Syndrome Score

The Systemic Inflammatory Response Syndrome (SIRS) score is calculated using four criteria: (1) body temperature greater than 38°C or less than 36°C; (2) heart rate greater than 90 beats per minute; (3) respiratory rate greater than 20 breaths per minute or arterial partial pressure of carbon dioxide (PaCO2) less than 32 mmHg; and (4) white blood cell count greater than 12,000/µL, less than 4,000/µL, or greater than 10% immature band forms. Each criterion present is assigned 1 point, producing a total score ranging from 0 to 4. Higher scores indicate a greater systemic inflammatory response and therefore a worse outcome. A total score of 2 or higher is considered positive for SIRS. The maximum SIRS score for each postoperative ICU day will be determined using the most abnormal values documented during that day.

Time frame
Postoperative day 2
3

Duration of Mechanical Ventilation

The outcome is defined as the total cumulative duration, measured in hours, during which the participant receives invasive mechanical ventilation from postoperative intensive care unit (ICU) admission until ICU discharge. The start and stop times of mechanical ventilation will be obtained from the nursing records. If a participant is extubated and subsequently reintubated during the same ICU stay, the durations of all invasive mechanical ventilation episodes will be summed. Time between ventilation episodes will not be counted.

Time frame
From postoperative ICU admission until final successful extubation, an average of 2 days.
4

Intensive Care Unit Length of Stay

Postoperative intensive care unit (ICU) length of stay is defined as the elapsed time, measured in days, from the documented time of postoperative ICU admission to the documented time of ICU discharge or transfer out of the ICU.

Time frame
From postoperative ICU admission until ICU discharge, an average of 4 days

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.